Announcement PDF ASX ANNOUNCEMENT RESULTS OF ANNUAL GENERAL MEETING MELBOURNE (AUSTRALIA) 14 November 2024: In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), the attached information is provided in relation to the resolutions put to shareholders of Invion Limited (ASX: IVX) (“Invion”) at its 2024 Annual General Meeting held earlier today. This announcement was approved for release by the Company Secretary of Invion Limited. ____________________________________________ Investor and Media enquiries: Thian Chew (Chairman & CEO) T: +61 3 9692 7222 E: investor@inviongroup.com Brendon Lau (Investor & Media Relations) M: +61 409 341 613 E: brendon.lau@inviongroup.com About Invion Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. It also holds the exclusive rights to the technology in Asia and Oceania, excluding China, Hong Kong, Taiwan, Macau, the Middle East and Russia for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States, Canada and Hong Kong for infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited. Invion is listed on the ASX (ASX: IVX). About Photodynamic Therapy (PDT) Invion is developing PhotosoftTM technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant “superbugs”. Invion Limited ABN 76 094 730 417 Level 4, 100 Albert Road, South Melbourne, VIC, 3205, Australia P: +61 9692 7222 W: www.inviongroup.com Invion Limited 2024 Annual General Meeting Thursday, 14 November 2024 Results of Meeting The following information is provided in accordance with section 251AA(2) of Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2. Resolution Details Instructions given to validly appointed proxies (as at proxy close) Number of votes cast on the poll (where applicable) Resolution Results Resolution Resolution Type For Against Proxy’s Discretion Abstain For Against Abstain* Carried / Not Carried Adoption of Remuneration Report Ordinary 519,590,630 96.48% 8,457,025 1.57% 10,489,025 1.95% 1,299,576 - 546,490,933 98.48% 8,457,025 1.52% 5,379,701 - Carried Election of Ms Melanie Leydin as a Director of the Company Ordinary 167,874,557 97.95% 615,716 0.04% 34,459,807 2.01% 710,696 - 222,185,767 99.72% 615,716 0.28% 710,696 - Carried 3. Re-election of Mr Alan Yamashita as a Director of the Company Ordinary 167,737,845 97.90% 5,376,928 0.31% 30,679,114 1.79% 1,097,291 - 213,828,237 97.55% 5,376,928 2.45% 5,537,416 - Carried 4. Ratification of prior issue of Lind Shares Ordinary 159,381,441 94.21% 899,424 0.05% 97,083,841 5.74% 22,734,114 - 256,565,282 99.65% 899,424 0.35% 22,174,239 - Carried 5. Appointment of Auditor Ordinary 170,014,247 99.16% 747,509 0.04% 13,641,806 0.80% - 183,756,053 99.59% 747,509 0.41% 4,440,125 - Carried Approval of Issue of Options to Directors Issue of Options to Mr Thian Chew Ordinary 112,478,640 96.45% 30,881,516 2.65% 10,489,025 0.90% 3,157,122 - 123,067,665 79.94% 30,881,516 20.06% 7,597,247 - Carried Approval of Issue of Options to Directors Issue of Options to Mr Alan Yamashita Approval of Issue of Options to Directors Issue of Options to Mr Alistair Bennallack 100:1 Consolidation of Capital of the Company Ordinary 165,916,904 97.56% 30,852,414 1.81% 10,687,034 0.63% 2,959,113 - 176,703,938 85.14% 30,851,414 14.86% 7,399,238 - Carried Ordinary 165,007,821 97.55% 30,881,516 1.83% 10,564,951 0.62% 3,257,122 - 175,672,772 85.05% 30,881,516 14.95% 7,697,247 - Carried Ordinary 166,866,473 97.47% 32,877,143 1.92% 10,489,025 0.61% 2,500,888 - 177,355,498 84.36% 32,877,143 15.64% 6,941,013 - Carried Approval of 10% Placement Facility Special 169,371,401 98.97% 7,245,351 0.42% 10,489,025 0.61% 3,083,397 - 179,960,426 96.13% 7,245,351 3.87% 175,584,964 Carried 1. 2. 6a. 6b. 6c. 7. 8. *Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.